FDA Biosimilar Meetings Offer Chance To Skip Clinical Trials
The U.S. Food and Drug Administration expects biosimilars makers to participate in exhaustive preapplication meetings with the agency, as detailed in new guidelines last week, but experts say the lengthy process...To view the full article, register now.
Already a subscriber? Click here to view full article